November 23, 2016 - By Clifton Ray
The Chief Executive Officer of Nxstage Medical Inc, Jeffrey Burbank has made a sudden transaction in the firm that is with a total value of $191,325 US Dollars. As exposed in the D.C. based-SEC electronic form filed on November 22, 2016, Jeffrey sold 7,500 shares at an average price-per-share of $25.5. And, It’s sure Jeffrey’s deal isn’t going to remain unnoticed as he today is having ownership of 905,116 shares – ( 1.47% of Nxstage Medical Inc’s Market Cap ).
Out of 6 analysts covering NxStage Medical (NASDAQ:NXTM), 5 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 83% are positive. $30 is the highest target while $14 is the lowest. The $23.10 average target is -5.68% below today’s ($24.49) stock price. NxStage Medical has been the topic of 7 analyst reports since November 4, 2015 according to StockzIntelligence Inc. On Tuesday, June 28 the stock rating was upgraded by Northland Capital to “Outperform”. The firm earned “Buy” rating on Friday, December 18 by BTIG Research. The stock has “Buy” rating given by Canaccord Genuity on Tuesday, August 2. Sterne Agee CRT initiated NxStage Medical, Inc. (NASDAQ:NXTM) on Friday, December 11 with “Buy” rating. The stock of NxStage Medical, Inc. (NASDAQ:NXTM) earned “Overweight” rating by Piper Jaffray on Thursday, March 31.
Insitutional Activity: The institutional sentiment increased to 1.2 in 2016 Q2. Its up 0.23, from 0.97 in 2016Q1. The ratio is positive, as 22 funds sold all NxStage Medical, Inc. shares owned while 45 reduced positions. 26 funds bought stakes while 39 increased positions. They now own 61.50 million shares or 4.11% more from 59.07 million shares in 2016Q1.
Hbk Ltd Partnership holds 0.01% or 54,300 shares in its portfolio. Citadel Advisors has invested 0% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Balyasny Asset Mngmt Limited Co holds 10,566 shares or 0% of its portfolio. Blair William & Il holds 1.19 million shares or 0.18% of its portfolio. Barnett Com holds 0.01% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM) for 500 shares. The North Carolina-based Natl Bank Of America De has invested 0% in NxStage Medical, Inc. (NASDAQ:NXTM). State Street reported 1.04M shares or 0% of all its holdings. Johnson Fin Gp has 0% invested in the company for 1,424 shares. Century Cos owns 61,284 shares or 0% of their US portfolio. Tudor Inv Corp Et Al reported 14,241 shares or 0.01% of all its holdings. Pura Vida Invs Lc, a New York-based fund reported 200,000 shares. Convergence Invest Prns Lc has invested 0.06% of its portfolio in NxStage Medical, Inc. (NASDAQ:NXTM). Deutsche Retail Bank Ag, a Germany-based fund reported 86,642 shares. Massachusetts Financial Co Ma accumulated 1.02 million shares or 0.01% of the stock. Teacher Retirement Of Texas accumulated 8,958 shares or 0% of the stock.
Insider Transactions: Since September 12, 2016, the stock had 0 buys, and 4 sales for $799,539 net activity. On Monday, November 21 the insider TOWSE MATTHEW W sold $112,789. $590,850 worth of NxStage Medical, Inc. (NASDAQ:NXTM) was sold by Turk Joseph E Jr. Another trade for 3,000 shares valued at $69,930 was made by MOORE CRAIG W on Monday, September 12.
The stock decreased 5.19% or $1.34 during the last trading session, hitting $24.49. About 676,148 shares traded hands or 74.69% up from the average. NxStage Medical, Inc. (NASDAQ:NXTM) has risen 63.69% since April 20, 2016 and is uptrending. It has outperformed by 59.13% the S&P500.
NxStage Medical, Inc. is a medical technology company. The company has a market cap of $1.56 billion. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. It currently has negative earnings. The Firm operates through three divisions: System One, In-Center and Services.
According to Zacks Investment Research, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.”
More recent NxStage Medical, Inc. (NASDAQ:NXTM) news were published by: Fool.com which released: “Here’s Why NxStage Medical, Inc.’s Stock Is Popping Today” on November 03, 2016. Also Fool.com published the news titled: “Home and Critical Care Drive NxStage Medical, Inc. Q2 Improvement” on August 04, 2016. Fool.com‘s news article titled: “Why NxStage Medical, Inc. Guided Lower Today” with publication date: February 10, 2016 was also an interesting one.
NxStage Medical, Inc., incorporated on October 20, 1998, is a medical technology company. The Firm is engaged in the development, manufacturing and marketing of services and products for patients suffering from chronic or acute kidney failure. The Firm operates through three divisions: System One, In-Center and Services. The Firm offers its services and products to various markets, such as home, critical care and in-center. The Company’s primary product, the System One, delivers the therapeutic flexibility and clinical benefits associated with dialysis machines that can be used by healthcare professionals and trained lay users alike in various settings, including patient homes, as well as traditional care settings, such as hospitals and dialysis centers. The Firm operates NxStage Kidney Care dialysis centers that treat end-stage renal disease patients directly.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray